The natural history and treatment outcome of blast phase BCR-ABL(−) myeloproliferative neoplasms

We analyzed the outcomes of 74 patients diagnosed with BCR-ABL(−) myeloproliferative neoplasms in blast phase receiving induction chemotherapy (55%), low-intensity therapy (16%), stem cell transplantation (SCT; 3%), or supportive care (26%). Median survival from the date of blastic transformation wa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tam, Constantine S., Nussenzveig, Roberto M., Popat, Uday, Bueso-Ramos, Carlos E., Thomas, Deborah A., Cortes, Jorge A., Champlin, Richard E., Ciurea, Stefan E., Manshouri, Taghi, Pierce, Sherry M., Kantarjian, Hagop M., Verstovsek, Srdan
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2008
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518875/
https://ncbi.nlm.nih.gov/pubmed/18566326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-138230
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars